Intraoperative Monitoring of the Pelvic Autonomic Nerves (NEUROS)
Primary Purpose
Rectal Cancer
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
TME
TME
Neuromonitoring
Sponsored by
About this trial
This is an interventional prevention trial for Rectal Cancer focused on measuring Rectal cancer, total mesorectal excision, pelvic autonomic nerve preservation, neurostimulation, urogenital function, quality of life
Eligibility Criteria
Inclusion Criteria:
- informed consent
- histologically confirmed carcinoma of the rectum (≤ 16 cm from anal verge)
- fit for radical surgery
- total mesorectal excision
- age 18-80 years
Exclusion Criteria:
- history of operation of the urinary tract (e.g. prostatectomy)
- pacemaker
- emergency operation
- multivisceral resection in the pelvis
- partial mesorectal excision
- eligibility for local excision (TEM, intestinal wall resection)
- ongoing infection or sepsis
- severe untreated physical or mental impairment
- pregnancy or breastfeeding
- women of childbearing potential who are not using a highly effective birth control method
- missing preoperative data on urogenital or anorectal function
- simultaneous participation in another clinical trial
- previous participation in this clinical trial
- lack of cooperation with the trial procedure
Sites / Locations
- Department of General and Visceral Surgery, University Medical Center Mainz
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
TME with neuromonitoring
TME without neuromontoring
Arm Description
Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
Outcomes
Primary Outcome Measures
Urogenital function
Increase of IPSS score by at least 5 points observed 12 months after surgery compared to the preoperative IPSS score per patient
Secondary Outcome Measures
Sexual function (females)
Reduction of FSFI score by at least 8 points 12 months after surgery compared to the preoperative FSFI score per patient.
Sexual function (males)
Reduction of IIEF score by at least 15 points 12 months after surgery compared to the preoperative IIEF score per patient.
Adverse events
Occurrence of adverse events.
Oncological safety
Rates of pCRM-positive specimen (distance of tumour from circumferential resection margin (CRM) ≤ 1mm).
Quality of mesorectal excision
Macroscopic assessment of the resection specimen.
Fecal incontinence
Evaluation of fecal incontinence using the Wexner-Vaizey score
Full Information
NCT ID
NCT01585727
First Posted
April 25, 2012
Last Updated
February 26, 2019
Sponsor
Johannes Gutenberg University Mainz
1. Study Identification
Unique Protocol Identification Number
NCT01585727
Brief Title
Intraoperative Monitoring of the Pelvic Autonomic Nerves
Acronym
NEUROS
Official Title
Continuous Intraoperative Monitoring of the Pelvic Autonomic Nerves During Total Mesorectal Excision (TME) for the Prevention of Urogenital and Anorectal Dysfunction in Patients With Rectal Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
June 2018 (Actual)
Study Completion Date
December 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johannes Gutenberg University Mainz
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
One of the major problems of rectal cancer surgery is pelvic autonomic nerve damage, which is the main cause of urogenital dysfunction influencing postoperative quality of life. Costs for diagnostics and treatment of short and long-term urogenital dysfunction are immense. Varying degrees of urogenital dysfunction are found in up to 32% and 55% of patients with rectal cancer despite potentially nerve-sparing total mesorectal excision (TME).
The study will examine the impact of a newly developed continuous monitoring device for preservation of urogenital function in patients with TME for rectal cancer. 188 patients will be included in the prospective, randomized, single-blind, parallel group multi-centre trial including two arms (TME with and without intraoperative continuous monitoring of pelvic autonomic nerves). The primary efficacy endpoint is the change in urinary function measured by International Prostate Function Score (IPSS) 12 months after surgery. Genital functions measured as secondary endpoints. The application of the continuous intraoperative neuromonitoring device could enhance the objective intraoperative confirmation of pelvic nerve sparing surgery. The investigators hypothesis is that the use of his device minimizes the risk of postoperative urogenital dysfunction in patients with TME for rectal cancer. An enormous reduction of treatment costs is to be expected.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer
Keywords
Rectal cancer, total mesorectal excision, pelvic autonomic nerve preservation, neurostimulation, urogenital function, quality of life
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
188 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TME with neuromonitoring
Arm Type
Experimental
Arm Description
Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
Arm Title
TME without neuromontoring
Arm Type
Active Comparator
Arm Description
Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
Intervention Type
Procedure
Intervention Name(s)
TME
Intervention Description
Total mesorectal excision
Intervention Type
Procedure
Intervention Name(s)
TME
Intervention Description
Total mesorectal excision
Intervention Type
Procedure
Intervention Name(s)
Neuromonitoring
Intervention Description
Intraoperative neuromonitoring of pelvic autonomic nerves.
Primary Outcome Measure Information:
Title
Urogenital function
Description
Increase of IPSS score by at least 5 points observed 12 months after surgery compared to the preoperative IPSS score per patient
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Sexual function (females)
Description
Reduction of FSFI score by at least 8 points 12 months after surgery compared to the preoperative FSFI score per patient.
Time Frame
12 months
Title
Sexual function (males)
Description
Reduction of IIEF score by at least 15 points 12 months after surgery compared to the preoperative IIEF score per patient.
Time Frame
12 months
Title
Adverse events
Description
Occurrence of adverse events.
Time Frame
12 months
Title
Oncological safety
Description
Rates of pCRM-positive specimen (distance of tumour from circumferential resection margin (CRM) ≤ 1mm).
Time Frame
12 months
Title
Quality of mesorectal excision
Description
Macroscopic assessment of the resection specimen.
Time Frame
1 day after the surgery
Title
Fecal incontinence
Description
Evaluation of fecal incontinence using the Wexner-Vaizey score
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
informed consent
histologically confirmed carcinoma of the rectum (≤ 16 cm from anal verge)
fit for radical surgery
total mesorectal excision
age 18-80 years
Exclusion Criteria:
history of operation of the urinary tract (e.g. prostatectomy)
pacemaker
emergency operation
multivisceral resection in the pelvis
partial mesorectal excision
eligibility for local excision (TEM, intestinal wall resection)
ongoing infection or sepsis
severe untreated physical or mental impairment
pregnancy or breastfeeding
women of childbearing potential who are not using a highly effective birth control method
missing preoperative data on urogenital or anorectal function
simultaneous participation in another clinical trial
previous participation in this clinical trial
lack of cooperation with the trial procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Werner Kneist, Univ.-Prof.
Organizational Affiliation
Department of Visceral and Abdominal Surgery, University Medical Center Mainz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of General and Visceral Surgery, University Medical Center Mainz
City
Mainz
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
27209237
Citation
Kauff DW, Kronfeld K, Gorbulev S, Wachtlin D, Lang H, Kneist W. Continuous intraoperative monitoring of pelvic autonomic nerves during TME to prevent urogenital and anorectal dysfunction in rectal cancer patients (NEUROS): a randomized controlled trial. BMC Cancer. 2016 May 21;16:323. doi: 10.1186/s12885-016-2348-4.
Results Reference
derived
Learn more about this trial
Intraoperative Monitoring of the Pelvic Autonomic Nerves
We'll reach out to this number within 24 hrs